|
Title
|
|
|
|
Antibiotic therapy for Klebsiella pneumoniae bacteremia : implications of production of extended-spectrum β-lactamases
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| The prevalence of extended-spectrum beta-lactamase (ESBL) production by Klebsiella pneumonia approaches 50% in some countries, with particularly high rates in eastern Europe and Latin America. No randomized trials have ever been performed on treatment of bacteremia due to ESBL-producing organisms; existing data comes only from retrospective, single-institution studies. In a prospective study of 455 consecutive episodes of Klebsiella pneumoniae bacteremia in 12 hospitals in 7 countries, 85 episodes were due to an ESBL-producing organism. Failure to use an antibiotic active against ESBL-producing K. pneumoniae was associated with extremely high mortality. Use of a carbapenem ( primarily imipenem) was associated with a significantly lower 14-day mortality than was use of other antibiotics active in vitro. Multivariate analysis including other predictors of mortality showed that use of a carbapenem during the 5-day period after onset of bacteremia due to an ESBL-producing organism was independently associated with lower mortality. Antibiotic choice is particularly important in seriously ill patients with infections due to ESBL-producing K. pneumoniae. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Clinical infectious diseases. - Chicago, Ill.
|
|
|
Publication
|
|
|
|
Chicago, Ill.
:
2004
|
|
|
ISSN
|
|
|
|
1058-4838
|
|
|
DOI
|
|
|
|
10.1086/420816
|
|
|
Volume/pages
|
|
|
|
39
:1
(2004)
, p. 31-37
|
|
|
ISI
|
|
|
|
000222087800007
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|